Sanofi's Sarclisa Secures FDA Approval For First-Line Multiple Myeloma, Marking Its Third US Approval
The FDA approved Sanofi's Sarclisa (isatuximab) in combination with VRd as a first-line treatment for newly diagnosed ...
The Pharma Letter4h
Sanofi’s Sarclisa gains third FDA approval
The US Food and Drug Administration (FDA) has approved Sarclisa (isatuximab) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) as a first line treatment option for adult patients ...
Medscape6h
Isatuximab Approved First-Line for Transplant-Ineligible MM
In addition to other MM indications, Isatuximab's anti-CD38 competitor on the US market, daratumumab (Darzalex — Johnson & Johnson), also carries a first-line indication for transplant-ineligible MM ...
The American Journal of Managed Care2d
FDA Approves Isatuximab With VRd as First-Line Option for Transplant-Ineligible Multiple Myeloma
Isatuximab (Sarclisa) with bortezomib, lenalidomide, and dexamethasone (VRd) is now an approved option for adults who cannot ...
oncnursingnews2d
FDA Approves Isatuximab Plus VRd for Newly Diagnosed Myeloma
The FDA approved isatuximab plus bortezomib, lenalidomide, and dexamethasone for patients with newly diagnosed myeloma who ...
Targeted Oncology2d
FDA Approves Isatuximab Plus VRd in Transplant-Ineligible Multiple Myeloma
The approval is supported by data from the phase 3 IMROZ study which demonstrated superior progression-free survival with ...
Cure Today3d
FDA Approves Sarclisa In Newly Diagnosed Transplant-Ineligible Multiple Myeloma
The Food and Drug Administration (FDA) has approved Sarclisa (isatuximab-irfc) with Velcade (bortezomib), Revlimid ...
Targeted Oncology5d
Positive Isa-VRd Trials in Transplant-Ineligible Myeloma Show New Approach
During a Case-Based Roundtable® event, Andrzej Jakubowiak, MD, PhD, discussed 2 recent trials in multiple myeloma for ...